How to buy Trevena stock | 2.59

Trevena, Inc is a biotechnology business based in the US. Trevena shares (TRVN) are listed on the NASDAQ and all prices are listed in US Dollars. Trevena employs 24 staff and has a trailing 12-month revenue of around USD$3 million.

How to buy shares in Trevena

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Trevena. Find the stock by name or ticker symbol: TRVN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Trevena reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.59, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Trevena, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Trevena. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Trevena's share price?

Since the stock market crash in March caused by coronavirus, Trevena's share price has had significant positive movement.

Its last market close was USD$2.59, which is 70.98% up on its pre-crash value of USD$0.7517 and 418.00% up on the lowest point reached during the March crash when the shares fell as low as USD$0.5.

If you had bought USD$1,000 worth of Trevena shares at the start of February 2020, those shares would have been worth USD$661.18 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,878.09.

Trevena share price

Use our graph to track the performance of TRVN stocks over time.

Trevena shares at a glance

• Key figures

Information last updated 2020-11-25.

Latest market close	USD$2.59
52-week range	USD$0.46 - USD$3.68
50-day moving average	USD$2.6822
200-day moving average	USD$2.0815
Wall St. target price	USD$5.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.262

Buy Trevena shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Trevena stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Trevena, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trevena price performance over time

Historical closes compared with the close of $2.59 from 2020-11-16

1 week (2020-11-16)	N/A
1 month (2020-10-27)	1.97%
3 months (2020-08-23)	N/A
6 months (2020-05-23)	N/A

1 year (2019-11-23)	N/A
2 years (2018-11-23)	N/A
3 years (2017-11-23)	N/A
5 years (2015-11-23)	N/A

Trevena financials

Revenue TTM	USD$3 million
Gross profit TTM	USD$31,000
Return on assets TTM	-16.74%
Return on equity TTM	-32.85%
Profit margin	0%
Book value	$0.708
Market capitalisation	USD$369 million

TTM: trailing 12 months

Shorting Trevena shares

There are currently 18.3 million Trevena shares held short by investors – that's known as Trevena's "short interest". This figure is 15.5% up from 15.9 million last month.

There are a few different ways that this level of interest in shorting Trevena shares can be evaluated.

Trevena's "short interest ratio" (SIR)

Trevena's "short interest ratio" (SIR) is the quantity of Trevena shares currently shorted divided by the average quantity of Trevena shares traded daily (recently around 3.6 million). Trevena's SIR currently stands at 5.11. In other words for every 100,000 Trevena shares traded daily on the market, roughly 5110 shares are currently held short.

However Trevena's short interest can also be evaluated against the total number of Trevena shares, or, against the total number of tradable Trevena shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevena's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Trevena shares in existence, roughly 150 shares are currently held short) or 0.1517% of the tradable shares (for every 100,000 tradable Trevena shares, roughly 152 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Trevena.

Find out more about how you can short Trevena stock.

Trevena share dividends

We're not expecting Trevena to pay a dividend over the next 12 months.

Trevena share price volatility

Over the last 12 months, Trevena's shares have ranged in value from as little as $0.46 up to $3.68. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevena's is 2.9735. This would suggest that Trevena's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Trevena overview

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Frequently asked questions

• What percentage of Trevena is owned by insiders or institutions?

  Currently 1.084% of Trevena shares are held by insiders and 11.647% by institutions.

• How many people work for Trevena?

  Latest data suggests 24 work at Trevena.

• When does the fiscal year end for Trevena?

  Trevena's fiscal year ends in December.

• Where is Trevena based?

  Trevena's address is: 955 Chesterbrook Boulevard, Chesterbrook, PA, United States, 19087

• What is Trevena's ISIN number?

  Trevena's international securities identification number is: US89532E1091

• What is Trevena's CUSIP number?

  Trevena's Committee on Uniform Securities Identification Procedures number is: 89532E109